Quanterix Corporation $(QTRX)$ reported its financial results for the second quarter ended June 30, 2025, revealing a net loss of $30.0 million, compared to a net loss of $7.4 million in the same period of the previous year. Despite challenges in the U.S. academic market, the company highlighted a net increase in new customers within its Accelerator business, although project sizes were smaller due to constrained biopharma budgets. Notably, revenues from Alzheimer's Diagnostics more than tripled year-over-year. The company ended the quarter with $263.8 million in cash, cash equivalents, marketable securities, and restricted cash, using approximately $5.7 million in cash. Looking forward, Quanterix expects 2025 revenues to range between $130 to $135 million, factoring in approximately two quarters of performance from Akoya Biosciences. On a pro forma basis, assuming a full-year combination with Akoya, projected revenues are expected to be between $165 and $170 million. The company anticipates a GAAP gross margin between 49% and 53%, with an adjusted gross margin ranging from 45% to 49%. Adjusted cash usage for 2025 is projected to be approximately $34 to $38 million, with the company expecting to exit the year with around $120 million in cash and cash equivalents and achieve cash flow breakeven in 2026. Significant business developments include the completion of the acquisition of Akoya Biosciences in early July, which has created an integrated platform for measuring biomarkers across the blood and tissue continuum. Furthermore, Quanterix launched p-Tau 205 and p-Tau 212 assays to advance Alzheimer's research at the Alzheimer's Association International Conference.